FRM
CLDX icon

Fox Run Management’s Celldex Therapeutics CLDX Stock Holding History

Fox Run Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,146
Closed -$390K – 956
2025
Q2 		$390K Sell
19,146
-13,524
-41% -$263K 0.06% 559
2025
Q1 		$593K Buy
32,670
+9,380
+40% +$210K 0.09% 414
2024
Q4 		$589K Buy
23,290
+13,966
+150% +$379K 0.11% 382
2024
Q3 		$317K Buy
+9,324
New +$355K 0.07% 521
2024
Q2 		– Sell
-4,824
Closed -$202K – 810
2024
Q1 		$202K Sell
4,824
-6,425
-57% -$264K 0.04% 632
2023
Q4 		$446K Buy
+11,249
New +$331K 0.11% 346

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return